LENZ Therapeutics, Inc. (LENZ)

Corporate Overview

LENZ Therapeutics is a pre-commercial biopharmaceutical company focused on the development and commercialization of the first and only aceclidine-based eye drop to improve near vision in people with presbyopia.

Our Leadership

Latest Financial Results

Q2 2024

Quarter Ended Jun 30, 2024

Earnings Release PDF

Earnings Webcast

10-Q PDF

XBRL

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Latest News

Oct 21, 2024 • 8:00 AM EDT

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

View Press Release View All News

Upcoming Event

Nov 7, 2024 4:30 pm CDT – 6:30 pm CDT

Academy 2024 Indianapolis

Add to Calendar View All Events

Email Alerts

Get the latest news and reports delivered right to your inbox.

IR Contacts

Corporate

LENZ Therapeutics, Inc.
201 Lomas Santa Fe Drive
Suite 300
Solana Beach, CA 92075
T: (888) 928-LENZ (5369)
contact@lenz-tx.com

Investor Relations

LENZ Therapeutics
IR@LENZ-Tx.com

Stern Investor Relations, Inc.
Janhavi Mohite
janhavi.mohite@sternir.com

Transfer Agent

Equiniti Trust Company, LLC
48 Wall Street
New York, NY 10005
T: 800-937-5449